Anavex Life Sciences (AVXL) vs Black Titan (BTTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anavex Life Sciences is the larger company by market cap ($137.7 million vs $6.6 million), about 20.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | BTTC |
|---|---|---|
| Share price | $1.49 | $0.48 |
| Market cap | $137.65M | $6.58M |
| 1-day change | -3.57% | -3.01% |
| YTD return | -56.74% | — |
| 1-year return | -84.37% | — |
| 5-year return | -91.21% | — |
| EPS (TTM) | $-0.14 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.53 | $10.05 |
| 52-week low | $1.47 | $0.342 |
| Distance from 52-week high | -84.41% | -95.22% |
| Analyst consensus | none | — |
| Average volume | 979.69K | 11.84M |
| Shares outstanding | 92.70M | 13.70M |
| Employees | 34 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anavex Life Sciences is about 20.9 times larger than Black Titan by market value ($137.65M vs $6.58M).
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
AVXL vs BTTC FAQ
Which is bigger, Anavex Life Sciences or Black Titan?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $137.65M compared with $6.58M for Black Titan (BTTC).
Are Anavex Life Sciences and Black Titan in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.